Mayo Clinic, Division of Gastroenterology and Hepatology, 20 First Street SW, Rochester, MN 55905, USA.
Expert Opin Pharmacother. 2010 Feb;11(3):387-92. doi: 10.1517/14656560903493460.
Primary biliary cirrhosis is a cholestatic liver disease that at one time was the leading indication for liver transplantation. Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis.
The treatment of primary biliary cirrhosis with a focus on ursodeoxycholic acid is covered. Papers related to treatment of primary biliary cirrhosis and associated conditions, using a variety of drugs but with a focus on ursodeoxycholic acid, are included. The papers reviewed date from 1984 - 2009.
The reader will gain an up-to-date understanding of current treatment strategies for primary biliary cirrhosis using ursodeoxycholic acid and an appreciation of what conditions are improved with this therapy and what associated conditions are not.
TAKE-HOME MESSAGE: Ursodeoxycholic acid in a dose of 13 - 15 mg/kg/day should be considered in all patients with primary biliary cirrhosis who have abnormal liver enzymes.
原发性胆汁性肝硬化是一种胆汁淤积性肝病,曾经是肝移植的主要适应证。熊去氧胆酸的治疗明显改善了原发性胆汁性肝硬化的自然病程。
重点介绍了熊去氧胆酸治疗原发性胆汁性肝硬化。本文纳入了使用各种药物治疗原发性胆汁性肝硬化及相关疾病的相关文献,但重点是熊去氧胆酸。综述中引用的文献时间跨度为 1984 年至 2009 年。
读者将了解到目前使用熊去氧胆酸治疗原发性胆汁性肝硬化的最新策略,并了解该疗法可改善哪些病症以及哪些相关病症无法改善。
对于所有肝功能异常的原发性胆汁性肝硬化患者,均应考虑使用剂量为 13-15mg/kg/天的熊去氧胆酸。